Expert Ratings for Krystal Biotech
Portfolio Pulse from Benzinga Insights
In the last quarter, Krystal Biotech (NASDAQ:KRYS) received 10 bullish ratings from analysts. The company's average 12-month price target has increased by 16.33% from the previous average, now standing at $135.1 with a high of $155.00 and a low of $102.00.
July 03, 2023 | 5:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Krystal Biotech received 10 bullish ratings from analysts in the last quarter. The average 12-month price target has increased by 16.33% to $135.1.
The increase in the average price target and the bullish ratings from analysts indicate a positive outlook for Krystal Biotech. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100